Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02475681
Title Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL
Acronym ElevateTN
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Acerta Pharma BV
Indications
Therapies
Age Groups: adult
Covered Countries USA | SWE | POL | NZL | LTU | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS


No variant requirements are available.